Free Daily Podcast Summary
Rheumnow Podcast: Daily Summaries Delivered
by Dr. Cush
Here and now
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- Today22 min
3 x IL-23 = IL do Better (11.6.2026)
Dr. Jack Cush reviews the FDA approvals and news reports from this past week on RheumNow.com. This week we discuss playing the numbers in rheumatology, playing the long game with stem cell transplants, and a=the Positive spin on seronegative RA.
- 4 days ago21 min
Individualized PsA Treatment With an IL-23i or a JAKi
In Part 2 of our series on managing the complexities of PsA, Saakshi Khattri, MD, and Lindsay Tom, PA-C, discuss their experience individualizing treatment for real patients with multidomain PsA and the IL-23i and JAKi data that informed their decisions. Sponsored by AbbVie Medical Affairs + Health Impact. https://rheumnow.com/therapeutic-update/individualized-psa-treatment-il-23i-or-jaki
- 6 days ago17 min
DERM on RheumNow PODCAST (October 2026)
Every day, every month, rheumatology publishes news and reports on JAK inhibitors, IL-17s, IL-23s, lupus, myositis, and scleroderma – all which could change how you practice dermatology. I'm Jack Cush from RheumNow, and This is Derm on RheumNow. This month’s podcast will Scratch the surface and find new drugs for dermographism, Hidradenitis, SLE, DLE & PsA. Probiotics loseout to placebo in PsA and Obesity sinks psoriasis biologics. This month: - The FDA is reviewing Sun Pharma’s tildrakizumab (Ilumya), an IL-23 inhibitor, for use in active psoriatic arthritis, with an October 29, 2026, action (PDUFA) date. Decisions to be based on PsA INSPIRE-1 and INSPIRE-2 Phase 3 Studies https://t.co/iDWhub0k91 - FDA has approved the IL-23 inhibitor tildrakizumab (Ilumya) use in adults with active psoriatic arthritis (PsA), expanding the interleukin indications beyond moderate-to-severe plaque psoriasis. (Based on INSPIRE-1/2; 800 adults, 52-week RCTs) https://buff.ly/xz2D3mc - FDA has approved rembrutinib (Rhapsido - BTK inhibitor from Novartis) as 1st Rx for adults with dermographism not controlled by H1 antihistamines (expanding its use beyond chronic spontaneous urticaria) https://buff.ly/xNfuSlh - Novartis announced that the European Commission has approved secukinumab (Cosentyx) for use in adults w/ polymyalgia rheumatica, not responding to GCs. SEC is 1st IL-17A inhibitor approved in Europe for PMR https://t.co/ASTwbSrGr2 - Merck MSD announced positive results w/ tulisokibart (anti-TL1A) in MK-7240-012, Phase 2b DBRPCT in mod-severe hidradenitis suppurativa. Wk 16 HiSCR50 responses were 72% (hi dose), 64% (mid dose), 52% (low dose) vs 35% PBO. https://t.co/cvBH0fvCnI https://t.co/jo7JaXMItZ - Biogen announced the 52-week OL results of AMETHYST Phase 2/3 RCT of litifilimab in 93 #CLE pts. Betw wk 24 & 52, pts improved w/ clear skin (27.2%; CLA IGA 0-1) & 29% CLASI-70 (dz activity) https://t.co/61zxVhUwuj - EADV abstract showed daxdilimab (anti-ILT7; on plasmacytoid dendritic cells) was effective in mod-severe discoid lupus. Ph II RCT 72 refract. DLE RCT; DAX vs PBO - ↓ CLASI-A vs placebo @24 wks. wk 4 50%+ CLASI-A ~62% vs 24% https://t.co/gJ4drxErGD - Italian retrospective study of 562 plaque psoriasis Rx w/ biologics - 34% were obese. Primary Rx failure signif. more w/ obesity (17% vs 6%; HR 2.75). A 5 kg/m2 BMI incr assoc w/ 37% higher risk. Lower risk of failure w/ IL-17i (HR 0.49) & IL-23i (HR 0.47). Obesity not assoc w/ secondary failures or safety D/Cs https://t.co/fUik6pBcnq - Tx persistence & response in PsA is a problem - influenced by demographics & Dz severity. 815 PsA pts in e Brit Society Rheumatology PsA Registe. @12 mos - 24% MDA, 24% ACR50. Median F/U 31 mos, only 65% still on index Rx. D/C higher w/ apremilast & w/ poorer baseline activity & PROs https://buff.ly/ZTZueX8 - Single center study of Probiotics in #PsA showed no benefit. 66 moderately active PsA pts (PASDAS 3.2+) on stable Tx: Rx probiotic vs PBO x 12 wks. 56 pts analyzed, PASDAS 3 responders: 43% probiotic vs 65% PBO (P 0.167), w/ no change in gut permeability markers or stool https://t.co/g6icpjuQOU - 92 early (~2 yrs) systemic sclerosis pts were treated with #MTX; 79% diffuse SSc. At 3 mos, 34% of dcSSc 25% reduction in mRSS - increasing to 62% 24 mos (29% at 24 mos ITT w/ non-responder imputation). GC did not improve skin. Dz progression seen w/ 75% of MTX monoTx D/C https://t.co/WvqyI8GKjT - Metanalysis of IVIG in scleroderma (11 studies, 363 pts) showed IVIG to be safe; signif improvement in skin by mRSS (SMD −0.59; p 0.0019) & GI Dz (SMD −0.73; p 0.0012; I2 = 0%). W/ inflam myopathy signif reduction in CK (SMD −0.53; p 0.001) https://t.co/h53FrACCgA https://t.co/qavoD3Vren - High TB & LTBI burden in Latin America.
- 1 weeks ago32 min
Mixed Drinks, Mixed Results (10.30.2026)
Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast – hopeful guidelines for PMR, certainty about good & bad beverages in gout; Mixed results in Sjogrens, non Lupus drugs saves Lupus lives and big hips sinks ships in Psoriatic arthritis.
- 1 weeks ago56 min
Advances and Challenges in Lupus Care: Insights from RheumNow Survey Findings
Listen to leading rheumatology and dermatology experts for an engaging discussion on the evolving landscape of Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE). Drawing on recent RheumNow survey findings, our expert panel explores real-world challenges in lupus assessment and management, clinical decision-making, disease activity evaluation, current treatment strategies, and emerging therapeutic approaches. Gain valuable perspectives on advances in lupus care, persistent unmet needs, and opportunities to improve patient outcomes. Expert Panelists: Victoria P. Werth, MD Joseph F. Merola, MD Maria Dall'Era, MD Moderator: Jack Cush, MD Sponsored by Biogen.
- 2 weeks ago16 min
Double Trouble (10.23.2026)
Dr. Jack Cush reviews the journal articles and regulatory announcements from this past week on RheumNow, including: two crystals in one joint; twice the cryptococcus risk in JAKs?; Myositis and Scleroderma; and a Sjögren’s patient with early damage has a greater than 2-fold risk of lymphoma. Double trouble week on the RheumNow podcast.
- 3 weeks ago30 min
Troubles with ‘Gut Feelings’
Dr. Jack Cush reviews this weeks news from RheumNow.com -- including placebo trumps controversial therapies, the dynamics of disease activity, fuze the big toe, and patients don’t appreciate being told “its all in your head”!
- 4 weeks ago27 min
Don’t Hold the JAK (10.9.2026)
On this weeks podcast Dr. Jack Cush reviews the news - Steroids are easy to start and hard to stop; hold the MTX but not the biologic or JAK, weighing in on avacopan, and age old messages for old age patients.
Get Rheumnow Podcast summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
Answers in CME
Our Skin: A Personal Discovery Podcast
People share personal experiences with skin conditions like psoriasis and HS, discussing diagnosis, treatment, and living fully despite challenges.
Untold Stories: Life with a Severe Autoimmune Condition
People share personal experiences living with rare autoimmune conditions like myasthenia gravis and CIDP, discussing diagnosis, treatment, and daily challenges.
The Curbsiders Internal Medicine Podcast
Expert-led internal medicine discussions with clinical insights and humor for primary care and hospital medicine providers.
Red Pill Your Healthcast
Two healthcare providers discuss overlooked health issues and empower listeners to make informed decisions for their families.
Skinquiries
Explores personal experiences of living with eczema and other visible or chronic skin conditions.
Symptomatic: A Medical Mystery Podcast
Patients battle undiagnosed illnesses as host Lauren Bright Pacheco investigates their journeys to uncover hidden medical conditions.
Get Better Faster
Doctors and researchers discuss functional medicine and root-cause approaches to chronic illness and health optimization.
Paul Saladino MD podcast
A physician explores the root causes of chronic disease and optimal health through science and personal experimentation.
JOSPT Insights
JOSPT
Frankly Speaking About Family Medicine
Discusses current topics and developments in primary care and family medicine.
This Week in Cardiology
A weekly summary and analysis of key developments in cardiology for healthcare professionals.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from Rheumnow Podcast in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's Rheumnow Podcast daily summary?
It's a free AI-powered email that summarizes new episodes of Rheumnow Podcast as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the Rheumnow Podcast podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official Rheumnow Podcast product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Dr. Cush.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
How often does Rheumnow Podcast release new episodes?
Rheumnow Podcast publishes every few days. Our AI generates a summary within hours of each new episode.
What topics does Rheumnow Podcast cover?
Rheumnow Podcast covers topics including Medicine, Fitness, Health & Fitness. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting Rheumnow Podcast summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.